Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-08-18
DOI
10.1093/ibd/izab158
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus
- (2020) Aurélien Amiot et al. DIGESTIVE AND LIVER DISEASE
- Infliximab therapy intensification upon loss of response: Is there an optimal trough level?
- (2019) Bella Ungar et al. DIGESTIVE AND LIVER DISEASE
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
- (2019) Christopher Andrew Lamb et al. GUT
- American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
- (2017) Niels Vande Casteele et al. GASTROENTEROLOGY
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Xavier Roblin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
- (2012) Filip Baert et al. Journal of Crohns & Colitis
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
- (2011) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now